title: Systematic Review and Meta-analysis of Flibanserin's Effects and Adverse Events in Women with Hypoactive Sexual Desire Disorder.
abstract: OBJECTIVE
  The efficacy and safety of flibanserin in the treatment of Hypoactive Sexual Desire Disorder (HSDD) is controversial. We reviewed existing evidence on the efficacy and safety of flibanserin in treating HSDD, and performed a meta-analysis of reported effects.
  
  
  METHODS
  Literature search was performed in PubMed, Scopus, and Cochrane library to find all trials on the efficacy of flibanserin in HSDD. Meta-analysis was performed using fixed- and random-effects models. Egger's test and "trim and fill" methods were used for the assessment of publication bias and imputation of potentially missing studies, respectively.
  
  
  RESULTS
  Among 105 studies that were initially found, only ten related documents (six published and four nonpublished studies) were included in the final analysis, comprising 8345 subjects (6113 and 2232 subjects in the flibanserin and placebo groups, respectively). Incomplete outcome data bias was probable in the included studies. Most studies had an acceptable validity and quality. There was no significant difference between flibanserin and placebo groups in most of the HSDD-assessed indices. Our results showed that although SSE, DSDS, FSFID and FSFI are significantly improved with flibanserin, this change did not reach statistical significance compared with placebo. For FSDSR-item 13 score and FSDSR total score, no significant difference was observed between flibanserin and placebo. The most common side effect of flibanserin was somnolence. The most common causes of heterogeneity were black ethnicity, duration of therapy, age of participants and duration of marital relationship.
  
  
  CONCLUSIONS
  the efficacy of flibanserin in women with HSDD was not found to be significantly different compared with placebo. Additional trials are required to clarify the efficacy of flibanserin for the treatment of HSDD.
authors: Behavioral Sciences Research Center, Baqiyatallah University of Medical Sciences, Tehran. Iran.
authors: Seyed Hassan
authors: SH
authors: Saadat
authors: Minimally Invasive Surgery Research Center; Iran University of Medical Sciences, Tehran. Iran.
authors: Ali
authors: A
authors: Kabir
authors: Kurdistan Research Center for Social Determinants of Health (KRCSDH), Kurdistan University of Medical Sciences, Sanandaj. Iran.
authors: Khaled
authors: K
authors: Rahmani
authors: Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran. Iran.
authors: Yunes
authors: Y
authors: Panahi
authors: Medical student, Student research Committee, Shiraz University of Medical Sciences, Shiraz. Iran.
authors: Milad
authors: M
authors: Hosseinialhashemi
authors: Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad. Iran.
authors: Amirhossein
authors: A
authors: Sahebkar
mesh_terms: D001562:Benzimidazoles / Q000009:adverse effects* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D020018:Sexual Dysfunctions, Psychological / Q000188:drug therapy*
chemical_list: D001562:Benzimidazoles; C098107:flibanserin
keywords: Flibanserin; meta-analysis; placebo; psychological; sexual dysfunctions